CX1440

Primary objectives: 1. Evaluate the safety and tolerability of single and multiple doses of CX1440 in healthy subjects; 2. Evaluate the effect of food on the pharmacokinetic characteristics of CX1440. Secondary objectives 1. Evaluate the pharmacokinetic characteristics of single and multiple doses of CX1440; 2. Measure pharmacodynamic (PD) parameters, including drug occupancy of the BTK target enzyme.

Primary objective To observe the safety and tolerability of oral CX1440 capsules at different doses in patients with relapsed/refractory B-lymphocyte malignancies and determine the possible maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary objective To investigate the pharmacokinetic (PK) parameters of single and multiple continuous oral administration of CX1440 capsules in humans. To measure pharmacodynamic (PD) parameters, including drug occupancy of BTK target enzyme. To preliminarily evaluate the clinical anti-tumor efficacy of CX1440 capsules.